|
Jun 26
|
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline
|
|
Jun 25
|
CRISPR Therapeutics AG (CRSP) Stock Moves 1.88%: What You Should Know
|
|
Jun 25
|
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
|
|
Jun 24
|
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
|
|
Jun 24
|
CRISPR Therapeutics AG (CRSP): A Bull Case Theory
|
|
Jun 24
|
Is CRISPR Therapeutics AG (NASDAQ:CRSP) Trading At A 45% Discount?
|
|
Jun 21
|
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
|
|
Jun 19
|
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
|
|
Jun 18
|
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
|
|
Jun 17
|
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
|
|
Jun 17
|
Cathie Wood's Flagship Ark Innovation ETF Is Booming Again. Here's Why.
|
|
Jun 11
|
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
|
|
Jun 10
|
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
|
|
Jun 7
|
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month
|
|
Jun 4
|
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
|
|
Jun 4
|
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?
|
|
Jun 3
|
The Best Stocks to Invest $1,000 in Right Now
|
|
Jun 2
|
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
|
|
May 29
|
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
|
|
May 21
|
Crispr Therapeutics call volume above normal and directionally bullish
|